Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574

A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Tg, K., Erdman, D. D., Cs, G., Zaki, Peret, T. C. T., Emery, S. L., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,353

Coronavirus as a possible cause of severe acute respiratory syndrome

Peiris, M. J. S., Lai, S., Poon, L. L. M., Guan, Y., Yam, L., Lim, W., Nicholls, J. M., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,916

Infectious Diseases

Blacklow, N. R., Gorbach, S. L., & Bartlett, J. G. (1992) · Cited by 2,753

Bats Are Natural Reservoirs of SARS-Like Coronaviruses

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C. S., Epstein, J. H., Wang, H., Crameri, G. S., Hú, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,571

Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477

Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China

Guan, Y., Zheng, B., He, Y., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S., Li, P. H., Zhang, L., Guan, Y., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,404

Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor

Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035

The Genome Sequence of the SARS-Associated Coronavirus

Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292

Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response

Glowacka, I., Bertram, S., Müller, M. A., Allen, P. W., Soilleux, E. J., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirß, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02232-10 · Cited by 1,130

Coronavirus vaccine development: from SARS and MERS to COVID-19

Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 486

Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies

Geller, C., Varbanov, M., & Duval, R. E. (2012) · Viruses · doi:10.3390/v4113044 · Cited by 444

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 434

The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors

Felberbaum, R. (2015) · Biotechnology Journal · doi:10.1002/biot.201400438 · Cited by 268

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity

Zhu, Y., Yu, D., Yan, H., Chong, H., & He, Y. (2020) · Journal of Virology · doi:10.1128/jvi.00635-20 · Cited by 227

Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies

Sardar, R., Satish, D., Birla, S., & Gupta, D. K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04658 · Cited by 182

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B., Jiang, S., & Zhou, Y. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.031 · Cited by 180

Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains

Padron-Regalado, E. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00300-x · Cited by 180

Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs

Sekimukai, H., Iwata‐Yoshikawa, N., Fukushi, S., Tani, H., Kataoka, M., Suzuki, T., Hasegawa, H., Niikura, K., Arai, K., & Nagata, N. (2019) · Microbiology and Immunology · doi:10.1111/1348-0421.12754 · Cited by 168

The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Acts as a Dominant Immunogen Revealed by a Clustering Region of Novel Functionally and Structurally Defined Cytotoxic T‐Lymphocyte Epitopes

Liu, J., Sun, Y., Qi, J., Chu, F., Wu, H., Gao, F., Li, T., Yan, J., & Gao, G. F. (2010) · The Journal of Infectious Diseases · doi:10.1086/656315 · Cited by 155

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Chen, W., Hotez, P. J., & Bottazzi, M. E. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1740560 · Cited by 140

Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management

Liu, M., Wang, T., Zhou, Y., Zhao, Y., Zhang, Y., & Li, J. (2020) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2020-0003 · Cited by 137

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity

Du, L., Kao, R. Y. T., Zhou, Y., He, Y., Zhao, G., Wong, C., Jiang, S., Yuen, K., Jin, D., & Zheng, B.-J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.092 · Cited by 131

Insect cell technology is a versatile and robust vaccine manufacturing platform

Mena, J. A., & Kamen, A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.24 · Cited by 124

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

Tai, W., Zhang, X., He, Y., Jiang, S., & Du, L. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104820 · Cited by 116

Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach

Ahammad, I., & Lira, S. S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.213 · Cited by 112

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 113

SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen

Wang, Y., Wang, L., Cao, H., & Liu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26320 · Cited by 94

Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection

Du, L., Zhao, G., Lin, Y., Chan, C. C. S., He, Y., Jiang, S., Wu, C. Y., Jin, D., Yuen, K., Zhou, Y., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.025 · Cited by 86

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

Lokugamage, K. G., Iwata‐Yoshikawa, N., Ito, N., Watts, D. M., Wyde, P. R., Wang, N., Newman, P. C., Tseng, C.-T. K., Peters, C. J., & Makino, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.092 · Cited by 73

Severe Acute Respiratory Syndrome and Coronavirus

Hui, D. S. C., & Chan, P. K. S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.04.009 · Cited by 72

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients

Cao, Z., Liu, L., Du, L., Zhang, C., Jiang, S., Li, T., & He, Y. (2010) · Virology Journal · doi:10.1186/1743-422x-7-299 · Cited by 72

Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects

Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ‪., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 73

The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review

Hou, Y., Lu, K., & Kuo, K. (2021) · Vaccines · doi:10.3390/vaccines9080885 · Cited by 71

Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics

Zhou, D., Tian, X., Qi, R., Peng, C., & Zhang, W. (2020) · Glycobiology · doi:10.1093/glycob/cwaa052 · Cited by 69

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

Escriou, N., Callendret, B., Lorin, V., Combredet, C., Marianneau, P., Février, M., & Tangy, F. (2014) · Virology · doi:10.1016/j.virol.2014.01.002 · Cited by 67

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

Zhu, Y., Yu, D., Han, Y., Yan, H., Chong, H., Ren, L., Wang, J., Li, T., & He, Y. (2020) · Science Advances · doi:10.1126/sciadv.abc9999 · Cited by 64

Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in mice

Lu, X., Chen, Y., Bai, B., Hu, H., Tao, L., Yang, J., Chen, J., Chen, Z., Hú, Z., & Wang, H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02676.x · Cited by 61

Virus-Like Particles of SARS-Like Coronavirus Formed by Membrane Proteins from Different Origins Demonstrate Stimulating Activity in Human Dendritic Cells

Bai, B., Hu, Q., Hu, H., Zhou, P., Shi, Z., Meng, J., Lu, B., Huang, Y., Mao, P., & Wang, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002685 · Cited by 59

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development

Ma, C., Su, S., Wang, J., Wei, L., Du, L., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.05.004 · Cited by 51

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview

Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55

Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic

Yu, M., Zhang, T., Zhang, W., Sun, Q., Li, H., & Li, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.628551 · Cited by 52

Protective and Pathologic Roles of the Immune Response to Mouse Hepatitis Virus Type 1: Implications for Severe Acute Respiratory Syndrome

Khanolkar, A., Hartwig, S. M., Haag, B. A., Meyerholz, D. K., Epping, L. L., Haring, J. S., Varga, S. M., & Harty, J. T. (2009) · Journal of Virology · doi:10.1128/jvi.00355-09 · Cited by 49

A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective Immunity

Du, L., Zhao, G., Chan, C. C. S., Li, L., He, Y., Zhou, Y., Zheng, B., & Jiang, S. (2010) · Viral Immunology · doi:10.1089/vim.2009.0090 · Cited by 47

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines

Jiang, S., Lu, L., Liu, Q., Xu, W., & Du, L. (2012) · Emerging Microbes & Infections · doi:10.1038/emi.2012.1 · Cited by 40

High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector

Sinegubova, M. V., Orlova, N. A., Kovnir, S. V., Dayanova, L. K., & Vorobiev, I. I. (2021) · PLoS ONE · doi:10.1371/journal.pone.0242890 · Cited by 39

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Du, L., Jin, L., Zhao, G., Sun, S., Li, J., Yu, H., Li, Y., Zheng, B., Liddington, R., Zhou, Y., et al. (2012) · Journal of Virology · doi:10.1128/jvi.02344-12 · Cited by 38

Retrospective study, full‐length genome characterization and evaluation of viral infectivity and pathogenicity of chimeric porcine deltacoronavirus detected in Vietnam

Saeng‐chuto, K., Jermsutjarit, P., Stott, C. J., Vui, D. T., Tantituvanont, A., & Nilubol, D. (2019) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13339 · Cited by 38

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients

Liu, L., Xie, J., Jianpin, S., Han, Y., Zhang, C., Fan, H., Liu, Z., Qiu, Z., He, Y., & Li, T. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.560184 · Cited by 36

Recombinant Ov -ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth Onchocerca volvulus , Can Directly Bind and Activate Antigen-Presenting Cells

He, Y., Barker, S. J., Macdonald, A., Yu, Y., Cao, L., Li, J., Parhar, R. S., Heck, S., Hartmann, S., Golenbock, D. T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800531 · Cited by 35

Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development

Khalaj‐Hedayati, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/7201752 · Cited by 35

Food Safety and Employee Health Implications of COVID-19: A Review

Trmčić, A., Demmings, E. M., Kniel, K. E., Wiedmann, M., & Alcaine, S. D. (2021) · Journal of Food Protection · doi:10.4315/jfp-21-201 · Cited by 41

Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies

Targovnik, A. M., Simonin, J. A., Callum, G. J. M., Smith, I., Warlet, F. U. C., Nugnes, M. V., Miranda, M. V., & Belaich, M. N. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11615-1 · Cited by 34

Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19

Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., MAMMADOVA, G., Özdarendeli, A., Yetişkin, H., Kaplan, B., Pavel, S. T. I., et al. (2021) · Vaccines · doi:10.3390/vaccines9111337 · Cited by 38

In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect

Boubaker, S., Othman, H., Touati, R., Ayouni, K., Lakhal, M., Ben‐Mustapha, I., Ghedira, K., Kharrat, M., & Triki, H. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04045-3 · Cited by 33

Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay

Sunwoo, H. H., Palaniyappan, A., Ganguly, A., Bhatnagar, P. K., Das, D., El‐Kadi, A. O. S., & Suresh, M. R. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.09.006 · Cited by 31

Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens

Lean, F. Z. X., Lamers, M. M., Smith, S. P., Shipley, R., Schipper, D., Temperton, N. J., Haagmans, B. L., Banyard, A. C., Bewley, K. R., Carroll, M. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78949-0 · Cited by 30

COVID‐19: Clinical status of vaccine development to date

Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32

Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks

Cao, M., Su, X., & Jiang, S. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.010 · Cited by 27

Baculovirus-Infected Insect Cells Expressing Peptide-MHC Complexes Elicit Protective Antitumor Immunity

Jordan, K. R., McMahan, R. H., Oh, J. Z., Pipeling, M. R., Pardoll, D. M., Kedl, R. M., Kappler, J. W., & Slansky, J. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.188 · Cited by 27

The Epitope and Neutralization Mechanism of AVFluIgG01, a Broad-Reactive Human Monoclonal Antibody against H5N1 Influenza Virus

Cao, Z., Meng, J.-Z., Li, X., Wu, R., Huang, Y., & He, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038126 · Cited by 27

Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected, Recovered) Modeling Using Empirical Infection Data

McMahon, A., & Robb, N. C. (2020) · JMIR Public Health and Surveillance · doi:10.2196/21168 · Cited by 28

Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain

Smaoui, M. R., & Yahyaoui, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-88696-5 · Cited by 21

Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections

Shanmugaraj, B., Siriwattananon, K., Malla, A., & Phoolcharoen, W. (2021) · Pathogens · doi:10.3390/pathogens10081051 · Cited by 23

Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development

Corral‐Lugo, A., López‐Siles, M., López, D., McConnell, M. J., & Martín-Galiano, A. J. (2020) · Vaccines · doi:10.3390/vaccines8030397 · Cited by 22

Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses

Venkataraman, S. (2022) · Vaccines · doi:10.3390/vaccines10111805 · Cited by 24

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

Rando, H. M., Lordan, R., Lee, A. J., Naik, A. S., Wellhausen, N., Sell, E., Kolla, L., Gitter, A., Greene, C. S., Bansal, V., et al. (2023) · mSystems · doi:10.1128/msystems.00927-22 · Cited by 22

Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress

Kovalenko, A. O., Ryabchevskaya, E. M., Evtushenko, E. A., Nikitin, N. A., & Karpova, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021701 · Cited by 21

Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses

Johnson, B. A., Graham, R. L., & Menachery, V. D. (2017) · Virology · doi:10.1016/j.virol.2017.12.009 · Cited by 19

Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro

Vishwakarma, P., Yadav, N., Rizvi, Z. A., Khan, N. A., Chiranjivi, A. K., Mani, S., Bansal, M., Dwivedi, P., Shrivastava, T., Kumar, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613045 · Cited by 18

Scope of Natural Plant Extract to Deactivate COVID-19Preprint

Shahid, M. A., Chowdhury, M. A., & Kashem, M. A. (2020) · doi:10.21203/rs.3.rs-19240/v1 · Cited by 18

Identification of a Potential mRNA‐based Vaccine Candidate against the SARS‐CoV‐2 Spike Glycoprotein: A Reverse Vaccinology Approach

Durojaye, O. A., Sedzro, D. M., Idris, M. O., Yekeen, A. A., Fadahunsi, A. A., & Alakanse, O. S. (2022) · ChemistrySelect · doi:10.1002/slct.202103903 · Cited by 16

Respiratory Virus Vaccines

Broadbent, A., Boonnak, K., & Subbarao, K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00059-8 · Cited by 18

Type IVB Pilus Operon Promoter Controlling Expression of the Severe Acute Respiratory Syndrome-Associated Coronavirus Nucleocapsid Gene in Salmonella enterica Serovar Typhi Elicits Full Immune Response by Intranasal Vaccination

Luo, F., Feng, Y., Liu, M., Li, P., Pan, Q., Jeza, V. T., Xia, B., Wu, J., & Zhang, X. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00076-07 · Cited by 16

mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development

Ilyichev, A. A., Orlova, L. A., Sharabrin, S. V., & Карпенко, Л. И. (2020) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj20.676 · Cited by 15

Development and Validation of a S1 Protein-Based ELISA for the Specific Detection of Antibodies against Equine Coronavirus

Zhao, S., Smits, C. B., Schuurman, N., Barnum, S. M., Pusterla, N., van Kuppeveld, F. J. M., Bosch, B., van Maanen, K., & Egberink, H. F. (2019) · Viruses · doi:10.3390/v11121109 · Cited by 16

In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses

Fard, S. N., Petrone, L., Petruccioli, E., Alonzi, T., Matusali, G., Colavita, F., Castilletti, C., Capobianchi, M. R., & Goletti, D. (2021) · BioMed Research International · doi:10.1155/2021/8856018 · Cited by 16

Insight into Vaccine Development for Alphacoronaviruses Based on Structural and Immunological Analyses of Spike Proteins

Shi, Y., Shi, J., Sun, L., Tan, Y., Wang, G., Guo, F., Hu, G., Fu, Y., Fu, Z. F., Xiao, S., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02284-20 · Cited by 14

Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31

Levi‐Schaffer, F., & de Marco, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15359 · Cited by 14

Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo

Yadav, N., Vishwakarma, P., Khatri, R., Siddqui, G., Awasthi, A., Ahmed, S., & Samal, S. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104843 · Cited by 14

Analysis of Codon Usage and Nucleotide Bias in Middle East Respiratory Syndrome Coronavirus Genes

Hussain, S., Shinu, P., Islam, M. M., Chohan, M. S., & Rasool, S. T. (2020) · Evolutionary Bioinformatics · doi:10.1177/1176934320918861 · Cited by 14

Identification of 22 N-glycosites on Spike Glycoprotein of SARS-CoV-2 and Accessible Surface Glycopeptide Motifs: Implications on Vaccination and Antibody TherapeuticsPreprint

Zhou, D., Qi, R., Zhang, W., Tian, X., & Peng, C. (2020) · Preprints.org · doi:10.20944/preprints202002.0381.v2 · Cited by 12

SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad

Natarelli, L., Virgili, F., & Weber, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212243 · Cited by 12

Misdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling and Clinical Detection Methods

Keaney, D., Whelan, S., Finn, K., & Lucey, B. (2021) · Medical Sciences · doi:10.3390/medsci9020036 · Cited by 12

Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants

Han, S., Lee, P., & Choi, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082114 · Cited by 11

Identification B and T-Cell epitopes and functional exposed amino acids of S protein as a potential vaccine candidate against SARS-CoV-2/COVID-19

Tohidinia, M., & Sefid, F. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104459 · Cited by 11

Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19

Lee, P., & Kim, D.-J. (2020) · Immune Network · doi:10.4110/in.2020.20.e28 · Cited by 12

Identification of a novel linear B-cell epitope in porcine deltacoronavirus nucleocapsid protein

He, W., Shi, X., Guan, H., Zou, Y., Zhang, S., Jiang, Z., & Su, S. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12348-5 · Cited by 10

A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission

Wu, R., Li, X., Leung, H.-C., Cao, Z., Qiu, Z., Zhou, Y., Zheng, B., & He, Y. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.005 · Cited by 10

Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro

Luan, N., Li, T., Wang, Y., Cao, H., Yin, X., Lin, K., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882856 · Cited by 9

A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge

Chen, Y., Wu, C. C., Yeo, Y., Xu, P., & Lin, T. L. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.01.009 · Cited by 10

SARS-CoV Spike Proteins Expressed by the Vaccinia Virus Tiantan Strain: Secreted SQ Protein Induces Robust Neutralization Antibody in Mice

Yan, K., Tan, W., Wang, H., Wang, Y., Zhang, X., Li, Y., & Ruan, L. (2009) · Viral Immunology · doi:10.1089/vim.2008.0064 · Cited by 9

Human Coronaviruses: Counteracting the Damage by Storm

Schoeman, D., & Fielding, B. C. (2021) · Viruses · doi:10.3390/v13081457 · Cited by 8

Review of Clinical Performance of Serology Based Commercial Diagnostic Assays for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies

Deshpande, P. S., Abraham, I. E., Pitamberwale, A., & Dhote, R. H. (2022) · Viral Immunology · doi:10.1089/vim.2020.0313 · Cited by 8

High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1 -based plasmid vectorPreprint

Sinegubova, M. V., Orlova, N. A., Kovnir, S. V., Dayanova, L. K., & Vorobiev, I. I. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.04.368092 · Cited by 8

Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China

Bai, Z., Li, Q., Chen, Q., Niu, C., Wei, Y., Huang, H., Zhao, W., Chen, N., Yao, X., Zhang, Q., et al. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.09.001 · Cited by 8

Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1

López, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071622 · Cited by 7

Identification and application of self-binding zipper-like sequences in SARS-CoV spike protein

Zhang, S. M., Liao, Y., Neo, T. L., Lu, Y., Liu, D. X., Vahlne, A. G., & Tam, J. P. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.05.012 · Cited by 6

Detection of SARS-CoV-2 in tissue: the comparative roles of RT-qPCR, in situ RNA hybridization, and immunohistochemistry

McHenry, A. J., Iyer, K., Wang, J., Liu, C., & Harigopal, M. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2085508 · Cited by 6

Immunogenicity of the spike glycoprotein of Bat SARS-like coronavirus

Hou, Y.-X., Peng, C., Han, Z., Zhou, P., Chen, J., & Shi, Z. (2010) · Virologica Sinica · doi:10.1007/s12250-010-3096-2 · Cited by 6

Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review)

Babaeimarzangou, S. S., Zaker, H., Soleimannezhadbari, E., Shamsi-Gamchi, N., Kazeminia, M., Tarighi, S., Seyedian, H., Tsatsakis, A. M., Spandidos, D. A., & Margina, D. M. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11741 · Cited by 5

Strategies for Designing Peptide Immunogens To Elicit α-Helical Conformation-Specific Antibodies Reactive with Native Proteins

Yan, Z., Hartsock, W. J., Qian, Z., Holmes, K. V., & Hodges, R. S. (2012) · ACS symposium series · doi:10.1021/bk-2012-1095.ch006 · Cited by 5

Generating stable chinese hamster ovary cell clones to produce a truncated SARS‐CoV spike protein for vaccine development

Lin, S., Leng, C., & Wu, S. (2010) · Biotechnology Progress · doi:10.1002/btpr.480 · Cited by 5

Koronaviruset – kryssimmunitet, flokkimmunitet og vaksineutvikling

Munthe, L. A. (2020) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.20.0298 · Cited by 3

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine

He, Y., Li, J., Du, L., Yan, X., Hu, G., Zhou, Y., & Jiang, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.054 · Cited by 62

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

He, Y., Zhu, Q., Liu, S., Zhou, Y., Baoan, Y., Li, J., & Jiang, S. (2005) · Virology · doi:10.1016/j.virol.2005.01.034 · Cited by 100

Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies

He, Y., Lü, H., Siddiqui, P., Zhou, Y., & Jiang, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4908 · Cited by 238

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

Zhou, Z., Post, P. L., Chubet, R. G., Holtz, K., McPherson, C. E., Petrić, M., & Cox, M. M. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.059 · Cited by 89

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

Chen, Z., Zhang, L., Qin, C., Ba, L., Yi, C. E., Zhang, F., Wei, Q., Tian, H., Yu, W., Yu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2678-2688.2005 · Cited by 181